FLGT - Fulgent Genetics Inc Stock Price, Fair Value and News

22.11USD-0.39 (-1.73%)Delayed

Market Summary

USD22.11-0.39

Delayed

-1.73%

FLGT Alerts

Losses in recent quarter

FLGT Stock Price

View Fullscreen

FLGT RSI Chart

FLGT Valuation

Market Cap

661.6M

Price/Earnings (Trailing)

-3.99

Price/Sales (Trailing)

2.3

EV/EBITDA

-4.33

Price/Free Cashflow

36.87

FLGT Price/Sales (Trailing)

FLGT Profitability

Operating Margin

37.47%

EBT Margin

-58.15%

Return on Equity

-14.72%

Return on Assets

-13.49%

Free Cashflow Yield

2.71%

FLGT Fundamentals

FLGT Revenue

Revenue (TTM)

287.5M

Rev. Growth (Yr)

-2.54%

Rev. Growth (Qtr)

-8.54%

FLGT Earnings

Earnings (TTM)

-165.9M

Earnings Growth (Yr)

15.06%

Earnings Growth (Qtr)

89.46%

Breaking Down FLGT Revenue

Last 7 days

1.7%

Last 30 days

10.1%

Last 90 days

-12.9%

Trailing 12 Months

-37.9%

How does FLGT drawdown profile look like?

FLGT Financial Health

Current Ratio

5.09

FLGT Investor Care

Shares Dilution (1Y)

0.75%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	287.5M	0	0	0
2023	364.9M	307.4M	286.4M	289.2M
2022	953.4M	869.8M	702.6M	619.0M
2021	773.4M	909.7M	1.0B	992.6M
2020	34.9M	43.8M	135.1M	421.7M
2019	22.1M	25.1M	29.8M	32.5M
2018	18.1M	18.8M	20.0M	21.4M
2017	20.1M	20.8M	20.3M	18.7M
2016	11.4M	13.2M	15.3M	18.3M
2015	3.4M	5.4M	7.5M	9.6M
2014	0	0	0	1.3M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Fulgent Genetics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 03, 2024	xie jian	sold (taxes)	-144,458	21.5	-6,719	president and coo
May 03, 2024	kim paul	sold (taxes)	-30,358	21.5	-1,412	cfo and treasurer
May 01, 2024	hsieh ming	sold (taxes)	-27,675	20.7	-1,337	chief executive officer
Apr 30, 2024	gao hanlin	sold (taxes)	-1,607	20.35	-79.00	chief scientific officer
Apr 26, 2024	xie jian	sold (taxes)	-87,314	20.1	-4,344	president and coo
Apr 26, 2024	kim paul	sold (taxes)	-55,033	20.1	-2,738	cfo and treasurer
Apr 26, 2024	gao hanlin	sold (taxes)	-23,195	20.1	-1,154	chief scientific officer
Mar 01, 2024	gao hanlin	sold (taxes)	-22,589	23.24	-972	chief scientific officer
Mar 01, 2024	xie jian	sold (taxes)	-34,372	23.24	-1,479	president and coo
Mar 01, 2024	kim paul	sold (taxes)	-36,091	23.24	-1,553	cfo and treasurer

Which funds bought or sold FLGT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-6.31	-177,465	420,481	-%
May 16, 2024	COMERICA BANK	reduced	-13.26	-100,737	187,987	-%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-53.5	-2,555,800	1,370,360	-%
May 15, 2024	Point72 Asia (Singapore) Pte. Ltd.	new	-	34,112	34,112	0.01%
May 15, 2024	DARK FOREST CAPITAL MANAGEMENT LP	new	-	319,641	319,641	0.05%
May 15, 2024	Gotham Asset Management, LLC	sold off	-100	-309,828	-	-%
May 15, 2024	OCCUDO QUANTITATIVE STRATEGIES LP	reduced	-40.26	-426,395	346,658	0.06%
May 15, 2024	Engineers Gate Manager LP	new	-	349,587	349,587	0.01%
May 15, 2024	Prime Capital Investment Advisors, LLC	reduced	-1.73	-80,614	226,613	-%
May 15, 2024	QUADRANT CAPITAL GROUP LLC	new	-	14,388	14,388	-%

Are Funds Buying or Selling FLGT?

Are funds buying FLGT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own FLGT

No. of Funds

FLGT Alerts

Losses in recent quarter

Unveiling Fulgent Genetics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jan 23, 2024	blackrock inc.	12.7%	3,761,878	SC 13G/A
Jan 26, 2023	blackrock inc.	12.0%	3,527,782	SC 13G/A
Jan 20, 2023	blackrock inc.	12.0%	3,527,782	SC 13G
Nov 10, 2022	hsieh ming	29.5%	8,684,102	SC 13D/A
Jan 27, 2022	blackrock inc.	11.5%	3,421,251	SC 13G/A
Jan 26, 2022	blackrock inc.	11.5%	3,421,251	SC 13G/A
Jul 12, 2021	blackrock inc.	10.5%	3,057,315	SC 13G/A

Recent SEC filings of Fulgent Genetics Inc

View All Filings

Date Filed	Form Type	Document
May 16, 2024	8-K	Current Report
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 03, 2024	8-K	Current Report
May 03, 2024	4	Insider Trading
May 03, 2024	10-Q	Quarterly Report
May 02, 2024	4	Insider Trading
Apr 30, 2024	4	Insider Trading
Apr 30, 2024	4	Insider Trading
Apr 30, 2024	4	Insider Trading

Peers (Alternatives to Fulgent Genetics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	196.9B	23.7B	11.04%	17.40%	44.73	8.29	-8.94%	-35.91%
A	45.2B	6.7B	14.64%	19.44%	36.57	6.71	-2.81%	-6.58%
IDXX	44.9B	3.7B	13.71%	10.52%	51.83	12.06	8.57%	23.94%
DGX	16.0B	9.3B	13.66%	10.24%	18.95	1.73	-3.29%	6.68%
NTRA	13.1B	1.2B	17.80%	114.36%	-35.76	10.81	39.26%	33.08%
MEDP	12.2B	2.0B	2.71%	87.82%	38.94	6.2	25.57%	21.62%
CRL	11.4B	4.1B	-3.66%	11.24%	26.02	2.78	0.49%	-11.59%
EXAS	9.3B	2.5B	-20.33%	-38.03%	-38.69	3.67	15.21%	53.51%
MID-CAP
GH	3.1B	603.7M	54.73%	-14.09%	-6.73	5.14	25.21%	30.68%
NEOG	2.9B	929.2M	11.70%	-18.80%	1.9K	3.16	28.93%	111.61%
SMALL-CAP
CDNA	808.3M	275.1M	87.44%	103.94%	-4.41	2.94	-13.93%	-126.97%
ACRS	84.8M	31.1M	-3.25%	-85.34%	-1.1	2.73	0.95%	19.75%
AWH	33.0M	9.2M	-24.07%	-37.65%	-2.24	3.6	11.85%	45.80%
APDN	2.5M	5.5M	-62.31%	120.18%	-0.2	0.45	-68.52%	-141.15%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

Fulgent Genetics Inc News

Latest updates

Fulgent Genetics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2
Revenue	-8.5%	64,485	70,505	84,687	67,853	66,168	67,704	105,655	125,341	222,805	320,268	251,671	227,868	153,616	359,429	294,978	101,716	17,265	7,753	8,387	10,347	8,424
Cost Of Revenue	-6.4%	42,381	45,276	44,843	47,281	47,357	54,717	59,560	60,065	-	77,725	62,134	43,466	35,858	74,075	51,772	26,261	7,717	4,057	3,634	3,885	3,620
Gross Profit	-12.4%	22,104	25,229	39,844	20,572	18,811	12,987	46,095	65,276	-	242,543	189,537	184,402	117,758	285,354	243,206	75,455	9,548	3,696	4,753	6,462	4,804
Operating Expenses	-75.1%	43,902	176,350	39,630	40,370	43,635	49,539	45,743	52,482	-	40,610	38,677	25,129	18,860	18,432	17,297	11,932	6,908	5,610	5,162	4,953	4,509
S&GA Expenses	-14.4%	8,989	10,500	10,161	10,723	10,083	10,253	9,859	10,866	-	7,940	8,200	6,012	5,219	5,008	5,081	5,014	3,260	1,597	1,635	1,687	1,304
R&D Expenses	-4.3%	11,434	11,952	10,014	9,692	9,782	8,509	7,507	6,905	-	5,989	7,464	6,021	5,312	5,422	4,576	3,177	1,849	1,978	1,795	1,744	1,574
EBITDA Margin	4.0%	-0.49*	-0.51*	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-	439	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	97.0%	-327	-10,846	20,300	-3,100	-5,200	-9,386	414	2,653	-	48,400	47,148	37,545	23,589	66,513	58,571	14,526	-599	34.00	-38.00	61.00	7.00
Earnings Before Taxes	90.2%	-14,173	-145,196	6,860	-14,700	-21,049	-33,462	1,757	13,752	-	201,978	150,825	159,769	99,502	267,204	226,498	63,944	2,915	-1,673	-160	1,698	487
EBT Margin	3.4%	-0.58*	-0.60*	-0.22*	-0.22*	-0.11*	0.30*	0.52*	0.67*	0.70*	0.64*	0.68*	0.73*	0.72*	-	-	-	-	-	-	-	-
Net Income	89.5%	-13,462	-127,714	-13,107	-11,590	-15,849	-23,832	1,719	11,099	-	153,557	104,339	122,522	79,812	200,691	166,307	46,638	3,321	-1,956	-296	1,462	331
Net Income Margin	0.8%	-0.58*	-0.58*	-0.22*	-0.16*	-0.07*	0.23*	0.39*	0.50*	0.53*	0.48*	0.51*	0.55*	0.54*	-	-	-	-	-	-	-	-
Free Cashflow	-72.9%	3,210	11,827	5,317	-2,407	-9,941	28,485	15,341	7,868	183,051	183,051	71,103	148,799	73,176	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-0.4%	1,230	1,235	1,358	1,355	1,377	1,386	1,406	1,462	1,466	1,279	1,205	1,050	999	700	247	96.00	89.00	89.00	61.00	56.00	56.00
Current Assets	-23.9%	387	508	550	528	581	628	697	675	765	612	623	567	659	524	196	41.00	37.00	37.00	39.00	35.00	36.00
Cash Equivalents	-43.9%	55.00	97.00	84.00	58.00	66.00	80.00	169	139	353	165	215	100	151	87.00	53.00	2.00	9.00	12.00	21.00	9.00	5.00
Net PPE	3.9%	87.00	83.00	85.00	88.00	79.00	81.00	82.00	86.00	69.00	62.00	60.00	51.00	47.00	40.00	17.00	6.00	6.00	6.00	6.00	6.00	6.00
Goodwill	0%	22.00	22.00	142	142	143	143	120	121	51.00	51.00	49.00	23.00	-	-	-	-	-	-	-	-	-
Liabilities	1.2%	103	102	97.00	91.00	108	116	124	151	153	113	160	129	198	131	60.00	9.00	8.00	6.00	7.00	5.00	6.00
Current Liabilities	4.0%	76.00	73.00	61.00	65.00	82.00	88.00	103	128	142	105	147	122	197	130	58.00	7.00	6.00	4.00	4.00	3.00	3.00
Shareholder's Equity	-0.8%	1,127	1,136	1,259	1,263	1,269	1,267	1,281	1,311	1,313	1,166	1,044	921	802	569	187	87.00	81.00	83.00	55.00	51.00	50.00
Retained Earnings	-2.1%	620	633	761	774	786	801	825	823	812	658	553	431	351	151	-15.43	-62.06	-65.39	-63.43	-63.13	-64.59	-64.93
Additional Paid-In Capital	1.9%	511	502	514	506	496	487	478	504	507	502	484	482	451	418	202	148	147	146	117	116	115
Shares Outstanding	0.8%	30.00	30.00	30.00	30.00	30.00	29.00	30.00	30.00	30.00	29.00	30.00	29.00	-	-	-	-	-	-	-	-	-
Minority Interest	-17.1%	-3.30	-2.81	3.00	4.00	4.00	3.00	4.00	6.00	7.00	7.00	8.00	8.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	629	-	-	-	978	-	-	-	1,600	-	-	-	191	-	-	-	39.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-51.3%	7,266	14,933	10,240	9,737	-7,907	33,207	20,776	11,126	188,411	77,086	152,201	76,111	233,179	134,256	9,415	-4,409	1,366	-116	3,903	675	1,055
Share Based Compensation	0.8%	11,518	11,432	10,902	10,323	10,265	10,022	8,972	8,030	5,616	5,020	4,374	3,526	2,962	3,003	3,150	1,080	924	938	951	737	583
Cashflow From Investing	-294.4%	-47,186	24,270	20,078	-1,096	-4,354	-92,599	44,289	-213,692	688	-140,259	-34,793	-155,005	-216,491	-318,767	-1,404	-2,405	-3,862	-36,079	6,344	3,211	-2,522
Cashflow From Financing	89.2%	-2,807	-25,951	-4,474	-16,259	-1,101	-29,593	-35,462	-11,152	-934	13,154	-2,989	27,893	47,347	218,903	42,571	-59.00	-164	27,639	1,127	5.00	4.00
Buy Backs	-99.0%	225	22,862	2,198	-	-	28,802	34,702	10,577	-	-	-	-	513	16.00	-	-	46.00	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

FLGT Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (unaudited) - USD ($) shares in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue	$ 64,485,000	$ 66,168,000
Cost of revenue	42,381,000	47,357,000
Gross profit	22,104,000	18,811,000
Operating expenses:
Research and development	11,434,000	9,782,000
Selling and marketing	8,989,000	10,083,000
General and administrative	21,489,000	21,802,000
Amortization of intangible assets	1,990,000	1,968,000
Total operating expenses	43,902,000	43,635,000
Operating loss	(21,798,000)	(24,824,000)
Interest and other income, net	7,625,000	3,775,000
Loss before income taxes	(14,173,000)	(21,049,000)
Benefit from income taxes	(327,000)	(5,200,000)
Net loss from consolidated operations	(13,846,000)	(15,849,000)
Net loss attributable to noncontrolling interests	384,000	509,000
Net loss attributable to Fulgent	$ (13,462,000)	$ (15,340,000)
Net loss per common share attributable to Fulgent:
Basic	$ (0.45)	$ (0.52)
Diluted	$ (0.45)	$ (0.52)
Weighted-average common shares:
Basic	29,769	29,536
Diluted	29,769	29,536

FLGT Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 54,677	$ 97,473
Marketable securities	251,018	326,681
Trade accounts receivable, net of allowance for credit losses of $25,831 and $25,226	52,060	51,132
Other current assets	28,754	32,559
Total current assets	386,509	507,845
Marketable securities, long-term	540,495	423,571
Redeemable preferred stock investment	20,438	20,438
Fixed assets, net	86,723	83,464
Intangible assets, net	140,989	143,053
Goodwill, net	22,055	22,055
Other long-term assets	32,676	34,902
Total assets	1,229,885	1,235,328
Current liabilities
Accounts payable	19,616	15,360
Accrued liabilities	25,918	30,737
Customer deposit	27,240	22,700
Contract liabilities	2,762	2,874
Notes payable, current portion	413	1,183
Other current liabilities	0	164
Total current liabilities	75,949	73,018
Deferred tax liabilities	7,405	7,962
Unrecognized tax benefits	5,978	5,978
Other long-term liabilities	13,907	15,084
Total liabilities	103,239	102,042
Commitments and contingencies (Note 8)
Stockholders’ equity
Common stock, $0.0001 par value per share, 50,000 shares authorized, 32,664 and 32,416 shares issued, respectively, and 29,890 and 29,653 shares outstanding, respectively	3	3
Preferred stock, $0.0001 par value per share, 1,000 shares authorized, no shares issued or outstanding
Additional paid-in capital	511,329	501,718
Accumulated other comprehensive (loss) income	(1,102)	1,205
Retained earnings	619,713	633,175
Total Fulgent stockholders' equity	1,129,943	1,136,101
Noncontrolling interest	(3,297)	(2,815)
Total stockholders’ equity	1,126,646	1,133,286
Total liabilities and stockholders’ equity	$ 1,229,885	$ 1,235,328

About Fulgent Genetics Inc

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and next generation sequencer services related to hereditary cancer, cardiovascular genetics, reproductive health, and neurodegenerative genetics, as well as pharmacogenetic tests. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to enhance the therapeutic window and pharmacokinetic profile, or PK profile, of new and existing cancer drugs. The company also operates picture genetics platform which includes proprietary gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.

CEO	Mr. Ming Hsieh
WEBSITE	fulgentgenetics.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	1012

Fulgent Genetics Inc Frequently Asked Questions

What is the ticker symbol for Fulgent Genetics Inc? What does FLGT stand for in stocks?

FLGT is the stock ticker symbol of Fulgent Genetics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Fulgent Genetics Inc (FLGT)?

As of Fri May 17 2024, market cap of Fulgent Genetics Inc is 661.63 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of FLGT stock?

You can check FLGT's fair value in chart for subscribers.

What is the fair value of FLGT stock?

You can check FLGT's fair value in chart for subscribers. The fair value of Fulgent Genetics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Fulgent Genetics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for FLGT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Fulgent Genetics Inc a good stock to buy?

The fair value guage provides a quick view whether FLGT is over valued or under valued. Whether Fulgent Genetics Inc is cheap or expensive depends on the assumptions which impact Fulgent Genetics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FLGT.

What is Fulgent Genetics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, FLGT's PE ratio (Price to Earnings) is -3.99 and Price to Sales (PS) ratio is 2.3. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FLGT PE ratio will change depending on the future growth rate expectations of investors.